Product
IGSC 20% infusion
1 clinical trial
1 indication
Indication
Primary Immunodeficiency DiseaseClinical trial
A Phase 3, Open-label, Non-controlled, Multi-dose, Extension Study to Evaluate the Long-term Safety and Tolerability of IGSC, 20% in Japanese Subjects With Primary Immunodeficiency Disease (PID)Status: Active (not recruiting), Estimated PCD: 2024-04-30